Atara Biotherapeutics (ATRA) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
1 Feb, 2026Opening remarks and agenda
CEO welcomed attendees, introduced board members, executive team, and external advisors present virtually.
Meeting officially called to order, with the agenda and voting procedures outlined.
Eight proposals were scheduled for stockholder consideration, with voting conducted online.
Board and executive committee updates
Board members and executive officers were introduced, including roles and responsibilities.
Shareholder proposals
Eight proposals included director elections, executive compensation, auditor ratification, equity and stock plans, reverse stock split, and potential adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Atara Biotherapeutics
- Registering 400,000 shares for resale by a key investor; no proceeds to the company from resale.ATRA
Registration Filing17 Mar 2026 - Returned to profitability in 2025 with a strengthened cash position and reduced expenses.ATRAQ4 202516 Mar 2026
- Allogeneic CAR T therapies advance toward US approval and global commercialization milestones.ATRAH.C. Wainwright 26th Annual Global Investment Conference 202414 Mar 2026
- All proposals passed, including director elections and auditor ratification, with no questions raised.ATRAAGM 20253 Feb 2026
- Allogeneic T-cell therapies advance in oncology and autoimmune disease, with US launch set for 2025.ATRAStifel's 2024 Virtual Cell Therapy Forum3 Feb 2026
- Allogeneic T-cell platform advances with key clinical milestones and strong financial runway.ATRASidoti Micro-Cap Virtual Conference2 Feb 2026
- First-in-class allogeneic T-cell therapy advances toward U.S. approval and clinical expansion.ATRACanaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026
- Allogeneic EBV T cell therapies advance in oncology and autoimmunity, with global milestones ahead.ATRAGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Allogeneic CAR-T platform advances with Tab-cel U.S. review and robust pipeline in oncology and autoimmunity.ATRA17th Annual LD Micro Main Event Conference17 Jan 2026